Scholar Rock (SRRK) Competitors

Scholar Rock (NASDAQ:SRRK) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Is SRRK or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Scholar Rock's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-145.60%	-91.83%
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%

Which has better earnings and valuation, SRRK or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$33.19M	84.39	-$165.79M	-$2.35	-12.73
Catalyst Pharmaceuticals	$460.48M	5.56	$71.41M	$1.18	18.20

Which has more risk & volatility, SRRK or CPRX?

Scholar Rock has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.

Does the MarketBeat Community prefer SRRK or CPRX?

Catalyst Pharmaceuticals received 331 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 74.70% of users gave Catalyst Pharmaceuticals an outperform vote while only 65.32% of users gave Scholar Rock an outperform vote.

Company	Underperform	Outperform
Scholar Rock	Outperform Votes 162 65.32%	Underperform Votes 86 34.68%
Catalyst Pharmaceuticals	Outperform Votes 493 74.70%	Underperform Votes 167 25.30%

Do analysts recommend SRRK or CPRX?

Scholar Rock presently has a consensus target price of $34.00, suggesting a potential upside of 13.64%. Catalyst Pharmaceuticals has a consensus target price of $31.14, suggesting a potential upside of 44.99%. Given Catalyst Pharmaceuticals' higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor SRRK or CPRX?

In the previous week, Scholar Rock and Scholar Rock both had 9 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.78 beat Scholar Rock's score of 0.18 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of SRRK or CPRX?

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 19.2% of Scholar Rock shares are owned by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Scholar Rock on 13 of the 18 factors compared between the two stocks.